Lin Y.-.YI-HSIN LIANGJIA-HUEI TSAIJAU-YU LIAUJIN-TUNG LIANGBEEN-REN LINJI-SHIANG HUNGLIANG-IN LINLI-HUI TSENGYIH-LEONG CHANGKUN-HUEI YEHANN-LII CHENG2020-02-242020-02-2420141932-6203https://www.scopus.com/inward/record.uri?eid=2-s2.0-84896861647&doi=10.1371%2fjournal.pone.0086789&partnerID=40&md5=a4bf69de2f692e455a223baa9f92fb57https://scholars.lib.ntu.edu.tw/handle/123456789/462213To identify better regimens in currently available chemotherapy would be beneficial to KRAS mutant metastatic colorectal cancer (mCRC) patients because they have fewer treatment options than KRAS wild-type mCRC patients. Clinicopathologic features and overall survival (OS) of KRAS mutant and wild-type mCRC patients who had used oxaliplatin-based, irinotecan-based, bevacizumab-based, as well as cetuximab-based regimens were compared to those who had never-used oxaliplatin-based, irinotecan-based, bevacizumab-based, as well as cetuximab-based regimens respectively. Between 2007 and 2012, a total of 394 mCRC patients, in whom 169 KRAS mutant and 225 KRAS wild-type, were enrolled. In KRAS mutant patients who had used oxaliplatin-based regimens (N = 131), the OS was significantly longer than that in KRAS mutant patients who had never-used oxaliplatin-based regimens (N = 38). The OS was 28.8 months [95% confidence interval (CI): 23.2-34.4] in KRAS mutant patients who had used oxaliplatin-based regimens versus 17.8 months [95% CI: 6.5-29.1] in KRAS mutant patients who had never-used oxaliplatin-based regimens (P = 0.026). Notably, OS in KRAS wild-type mCRC patients who had used oxaliplatin-based regimens (N = 185) was not significantly longer than that in KRAS wild-type mCRC patients who had never-used oxaliplatin-based regimens (N = 40) (P = 0.25). Furthermore, the OS in KRAS mutant patients who had used either irinotecan-based, bevacizumab-based or cetuximab-based regimens was not significantly different than that in KRAS mutant patients who had never-used either irinotecan-based, bevacizumab-based or cetuximab-based regimens respectively. In multivariate analyses, patients who had used oxaliplatin-based regimens remains an independent prognostic factor for longer OS in KRAS mutant mCRC patients. In conclusion, oxaliplatin-based regimens are more beneficial in KRAS mutant than in KRAS wild-type mCRC patients. ? 2014 Lin et al.[SDGs]SDG3bevacizumab; cetuximab; irinotecan; oxaliplatin; KRAS protein, human; oncoprotein; oxaliplatin; platinum complex; Ras protein; adult; aged; article; cancer prognosis; cancer survival; controlled study; drug use; female; gene mutation; human; major clinical study; male; metastatic colorectal cancer; oncogene K ras; overall survival; survival rate; survival time; treatment outcome; very elderly; wild type; young adult; Colorectal Neoplasms; drug administration; genetics; metastasis; middle aged; multivariate analysis; mutation; pathology; proportional hazards model; survival; time; tumor recurrence; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Proportional Hazards Models; Proto-Oncogene Proteins; ras Proteins; Survival Analysis; Time Factors; Treatment Outcome; Young Adultjournal article10.1371/journal.pone.0086789245052652-s2.0-84896861647